What Is the MHRA Investigating?

The MHRA is investigating UK clinics that promote peptide injections with medicinal claims, meaning claims that a product treats, prevents or improves a condition, which the regulator says those clinics are not permitted to make. The inquiry followed a newspaper investigation published in early April 2026, and the MHRA's position is that if a clinic makes medicinal claims for a peptide, the product is treated as a medicine and falls under the Human Medicines Regulations 2012 12.

This page answers the questions the inquiry raises, in the order people tend to ask them. It does not attempt a full account of the inquiry or a general guide to UK law, and it is not legal advice. For the general picture of how the legal status of peptides is decided, the site's getting-started article on whether peptides are legal is the place to begin.

What prompted the inquiry?

A Guardian investigation into UK clinics advertising peptide injections did. The paper examined clinic websites and spoke to clinicians, and found compounds such as BPC-157, Cortexin and thymosin alpha described online in terms of tissue repair, protecting the brain and supporting immune function, despite the limited human evidence behind any of those descriptions 23.

Coverage also noted a telling contradiction. Some clinics listed peptides with stated benefits, prices and treatment durations while at the same time labelling the products "research only" 3. That combination is the crux of what the regulator has said since.

Who exactly is being investigated?

Clinics that offer peptide injections and make medicinal claims about them. The MHRA's statement, as reported, was framed around clinics: if clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation, and the agency will take action against clinics identified as breaching the legal requirements 2.

Some secondary accounts describe the inquiry as extending to retailers as well. We could not confirm that from the regulator's own words, so this page does not assert it. What can be said is that the MHRA's comments about "research purposes" statements were not limited to clinics, and the legal test it described applies to anyone who promotes a product 1.

Which law would a clinic be breaking?

The Human Medicines Regulations 2012, the main body of UK medicines law. They define a medicinal product, require a marketing authorisation before a medicine is sold or supplied, and in a dedicated part regulate how medicines may be advertised 4.

The advertising rules matter as much as the authorisation rules here. The MHRA's guidance on advertising and promotion, known as the Blue Guide, sets out how the agency applies those provisions, and the basic position is that a medicine without an authorisation may not be advertised at all 5. A clinic that promotes a peptide with medicinal claims therefore runs into two problems at once: the product is an unlicensed medicine, and the promotion is advertising of an unlicensed medicine.

What is the claims test?

It is the question of what a product is presented as being for, and the answer decides which regulatory framework applies. The MHRA put it directly: peptide products may be sold as cosmetics, supplements and medicines, and depending on their intended purpose they fall under different frameworks, with classification decided case by case 1.

In practice the test looks at everything surrounding a product, not just its name. The UK definition of a medicinal product, like the European one it descends from, catches a substance presented as having properties for treating or preventing disease in people, as well as one used to restore, correct or modify physiological functions 4. A website description, a consultation script, a price list quoting a course of treatment or a line about recovery can each be evidence of that presentation.

Does a "research use only" label protect a seller?

Not when the label is contradicted by everything around it. The MHRA said that it disregards claims that products are for "research purposes" if it is clear that such claims are being used as an attempt to avoid medicines regulations, and that where promotional material shows the products are in fact unauthorised medicines intended to be given to people, it will take appropriate regulatory action 1.

That is a consequence of the presentation test rather than a new rule. A label is one piece of the presentation. If a website offers injection appointments, lists benefits and quotes treatment durations, the words "research only" at the bottom of the page do not change what the page as a whole is presenting.

Has the MHRA banned any peptides?

No. Nothing in the regulator's public statements announces a ban on any substance or moves any peptide into a new legal category 12. The inquiry is about claims and conduct, and a peptide's status turns on how it is presented and supplied, which is exactly why the same compound can be treated differently in different hands.

This is worth stating because some coverage has described the inquiry as a crackdown on peptides as such. That is not what the MHRA has said. It has said that clinics may not make medicinal claims for unlicensed products.

What does it mean for laboratory research reagents?

Very little changes in law, and one thing is clarified in practice. Material supplied to laboratories without any claim about treating people is not what the inquiry describes, because the problem the MHRA identified is medicinal presentation 12. At the same time, the regulator's comments make plain that a research designation is judged by conduct, not by wording.

So the inquiry sharpens a line that already existed. On one side is supply that makes no claim about people and is presented as laboratory material throughout. On the other is anything that presents a product as a treatment, however it is labelled. The inquiry targets the second, and it gives no new assurance to the first.

Why does the regulator care about clinics in particular?

Because clinics are where claims meet patients. A clinic has a clinician, a consultation and an appointment, all of which lend a product the authority of medicine, and the reporting that triggered the inquiry found clinic staff suggesting peptides for specific complaints 26.

The concern is reinforced by the evidence gap. Reporting on the inquiry noted that there is little scientific evidence in humans to support the health and wellness claims being made, which is what makes medicinal promotion of these products a regulatory problem rather than simply an advertising one 6.

What could happen to a clinic found in breach?

The MHRA has said it will take action against clinics identified as breaching the legal requirements, without setting out in public what that action will be in any given case 2. The Human Medicines Regulations contain both authorisation and advertising offences, and the agency's advertising guidance describes how it handles promotion that breaches the rules 45.

Beyond that we would be guessing. At the time of writing we have not found a published outcome of the inquiry, and this page does not predict one.

Why would a clinic label a product "research only" at all?

Presumably because the phrase is the ordinary description of material supplied outside the medicines system, and borrowing it suggests the product sits outside that system too. The reporting found exactly that pairing: products described as research-only on the same pages that listed benefits, prices and courses of treatment 3.

The MHRA's answer is that the pairing does not work. A designation that describes laboratory supply cannot sit coherently beside an offer to treat patients, and where the two appear together the regulator reads the offer, not the label 1. The label then stops being a description of the supply channel and becomes, in the regulator's words, an attempt to avoid medicines regulation.

Does the inquiry cover the whole of the UK?

The law it rests on does. The Human Medicines Regulations 2012 apply across England, Scotland, Wales and Northern Ireland, and the MHRA is the medicines regulator for the whole of the United Kingdom 4. Reporting on the inquiry did not describe it as limited to any one nation, and the claims test it applies is the same everywhere in the UK.

Is this connected to the FDA's changes in the United States?

No. The FDA's April 2026 action concerned which bulk substances American compounding pharmacies may use, and it has no legal effect in the United Kingdom. The MHRA's inquiry is about promotional claims under UK medicines law. The two happened in the same month and are sometimes reported together, but they answer different questions under different statutes.

So what is the MHRA investigating, in one sentence?

Whether UK clinics are promoting unlicensed peptide injections as treatments, which would make those products medicines and the promotion unlawful 12. Everything else, from the status of research labels to the question of penalties, follows from that single test of presentation.